A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Exclusion Criteria

• •1. Previous exposure to immune-mediated therapy; previous use of antitumor vaccine;
• •2. Received the last anti-tumor therapy within 4 weeks prior to the first dose of study drug;
• •3. Received any investigational agent within 4 weeks prior to the first dose of study drug;
• •4. Received systemic treatment with Chinese herbal medicine indicated for cancer or drugs used for immunoregulation (including thymosin, interferon, interleukin, except for local use for pleural effusion) within 2 weeks before the first dose;
• •5. Are participating in another interventional clinical study, or observational (non-interventional) clinical study or in the follow-up phase of an interventional study;